Company profile

Profile of Consun Pharmaceutical Group


Consun Pharmaceutical Group (HK.01681) is a modern pharmaceutical enterprise that integrates R&D, production and marketing. It’s founded in 1997 and listed in Hong Kong in 2013. It owns subordinate companies including Guangzhou Consun Pharmaceutical Co. Ltd, Consun Pharmaceutical (Inner Mongolia) Co. Ltd, Guangxi Yulin Pharmaceutical Group Co. Ltd, Consun Pharmaceutical (Horgos) Co. Ltd, etc. and operates well-known brands including Consun, Yulin etc. In 2019, Consun won the title of Benchmark Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of the People's Republic of China. In 2020, Consun was awarded the Influential Brand of Guangdong Pharmaceutical Industry. In 2021, Consun won the Most Valuable Brand Award in the Best Listed Company in Greater China by GuruClub, the SRDI SMEs in Guangdong Province and the Outstanding Contribution Enterprise in the Anti-epidemic Campaign in 2020. In 2023, Consun Pharmaceutical Group ranked 22nd on the 2022 TOP100 Chinese Medicine Enterprises List, with a brand value of 11.236 billion yuan.

Consun has four production bases located in Guangzhou in Guangdong Province, Tongliao in Inner Mongolia Autonomous Region, Yulin in Guangxi Province and Horgos in Xinjiang Autonomous Region and more than 3000 employees. Consun Pharmaceutical Group strives to create a "1+6" product pattern, with Nephrology as the flagship and developing Imaging, Women & Children, Orthopedics, Dermatology, Hepatobiliary, Gastroenterology simultaneously and has a rich product portfolio and continuously carrying out new technological innovation and product R&D. It has 138 medicines including 62 traditional Chinese medicines and 76 western medicines. 33 medicines enter the National Essential Medicines List and 67 medicines enter the National Health Insurance List. Bone-setting Liquid got listed in the Chinese Geographical Indication Product Dictionary in 2010. With efficient, elite and professional marketing teams covering both hospitals and OTC fields and distribution network throughout the country, Consun business performance has always maintained stable and rapid growth.

Consun owns a Nephropathy Medicines Research Center invested by enterprise, 1 Postdoctoral Scientific Research Workstation, 2 provincial Engineering Technical Research Center and 3 provincial Enterprise Technical Research Center and carries out in-depth cooperation with Hong Kong Baptist University, Macao University of Science and Technology, Southern Medical University and other famous universities.

In future, Consun will adhere to the mission of making innovations from inheriting traditions and making good medicines to benefit people and strive to make Consun a first-class modern pharmaceutical enterprise with nephrology as the flagship and leadership in multi-specialty and make contribution to the health of human beings.